Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q3 2016 (← Previous) (Next →)

Filing Date: Oct 24, 2016

Total Value ($000): $89,691,642 (100.0% shares, 0.0% debt)

Holdings (7)

— Audentes Therapeutics, Inc. 35.9%

Value ($000) $32,179,678 Shares 1,806,832 Est. Cost $17810.00 Unrealized —

— Immune Design Corp. 18.7%

Value ($000) $16,738,232 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 17.0%

Value ($000) $15,219,688 Shares 2,215,384 Est. Cost $20.09 Unrealized -69.7%

— Clovis Oncology, Inc. 16.4%

Value ($000) $14,687,347 Shares 407,416 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 6.8%

Value ($000) $6,136,718 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

GKOS Glaukos Corporation 3.0%

Value ($000) $2,695,693 Shares 71,428 Est. Cost $30.09 Unrealized +10.0%

— CymaBay Therapeutics, Inc. 2.3%

Value ($000) $2,034,286 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Audentes Therapeutics, Inc.	1,806,832	$32,179,678	35.9%	$17810.00	—	Common Stock	05070R104
—	Immune Design Corp.	2,208,210	$16,738,232	18.7%	$7580.00	—	Common Stock	45252L103
OCUL	Ocular Therapeutix, Inc.	2,215,384	$15,219,688	17.0%	$20.09	-69.7%	Common Stock	67576A100
—	Clovis Oncology, Inc.	407,416	$14,687,347	16.4%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$6,136,718	6.8%	$13050.00	—	Common Stock	004449104
GKOS	Glaukos Corporation	71,428	$2,695,693	3.0%	$30.09	+10.0%	Common Stock	377322102
—	CymaBay Therapeutics, Inc.	1,048,601	$2,034,286	2.3%	$9830.00	—	Common Stock	23257D103